Effect of Levosimendan on Diastolic Function in Patients Undergoing Coronary Artery Bypass Grafting: A Comparative Study

Journal of Cardiovascular Pharmacology

Volumn 66, Issue 2, 2015, Pages 141-147

  Malik, Vishwas ^a   Subramanian, Arun ^a   Hote, Milind ^a   Kiran, Usha ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

coronary artery bypass; echocardiography; Levosimendan; nitroglycerin; pro brain natriuretic peptide; transesophageal

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GLYCERYL TRINITRATE; LEVOSIMENDAN; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN; VASODILATOR AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIASTOLIC DYSFUNCTION; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAXATION TIME; STERNOTOMY; TISSUE DOPPLER IMAGING; TREATMENT RESPONSE; ADVERSE EFFECTS; AGED; BLOOD PRESSURE; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DIASTOLE; DRUG EFFECTS; MIDDLE AGED; PHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

AGED; BLOOD PRESSURE; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DIASTOLE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PYRIDAZINES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84939620975     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000256     Document Type: Article

References (32)

1. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539-2550.
2. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282-2289.
3. Angeja BG, Grossman W. Evaluation and management of diastolic heart failure. Circulation. 2003;107:659-663.
4. Grewal J, McKelvie R, Lonn E, et al. BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction. Eur J Heart Fail. 2008;10:252-259.
5. Tursun I, Gursoy MO, Ulas T, et al. Levosimendan improves NTproBNP levels and echocardiographic parameters in patients with decompensated heart failure submitted to optimal medical therapy. Koysulu Heart J. 2014;17:37-41.
6. Jörgensen K, Bech-Hanssen O, Houltz E, et al. Effects of levosimendan on left ventricular relaxation and early filling at maintained preload and afterload conditions after aortic valve replacement for aortic stenosis. Circulation. 2008;117:1075-1081.
7. Levin R, Degrange M, Del Mazo C, et al. Preoperative levosimendan decreases mortality and the development of low cardiac output in highrisk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol. 2012;17:125-130.
8. Tritapeppe L, De Santis V, Vitale D, et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anesth. 2009;102:198-204.
9. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107-133.
10. Ohara T, Little WC. Evolving focus on diastolic dysfunction in patients with coronary artery disease. Curr Opin Cardiol. 2010;25:613-621.
11. Gorcsan J, Diana P, Lee J, et al. Reversible diastolic dysfunction after successful coronary artery bypass surgery. Assessment by transesophageal Doppler echocardiography. Chest. 1994;106:1364-1369.
12. Carroll JD, Hess OM, Hirzel HO, et al. Left ventricular systolic and diastolic function in coronary artery disease: effects of revascularization on exercise-induced ischemia. Circulation. 1985;72:119-129.
13. Dernellis J, Panaretou M. Effects of levosimendan on restrictive left ventricular filling in severe heart failure. Chest. 2005;128:2633-2639.
14. Parissis JT, Panou F, Farmakis D, et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol. 2005;96: 423-426.
15. Ikonomidis I, Parissis JT, Paraskevaidis I, et al. Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure. Eur J Heart Fail. 2007;9:1172-1177.
16. Lavine SJ, Campbell CA, Held AC, et al. Effects of nitroglycerininduced reduction of left ventricular filling pressure on diastolic filling in acute dilated heart failure. J Am Coll Cardiol. 1989;14:233-234.
17. Sage PR, de la Lande IS, Stafford I, et al. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation. 2000;102:2810-2815.
18. Kivikko M, Lehtonen L. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des. 2005;11: 435-455.
19. Lewis BS, Lewis N, Sapoznikov D, et al. Isovolumic relaxation period in man. Am Heart J. 1980;100:490-499.
20. De Luca L, Sardella G, Proietti P, et al. Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echocardiographic study. J Am Soc Echocardiogr. 2006;19:172-177.
21. Furber AP, Prunier F, Nguyen HCP, et al. Coronary blood flow assessment after successful angioplasty for acute myocardial infarction predicts the risk of long-term cardiac events. Circulation. 2004;110: 3527-3533.
22. Duman D, Palit F, Simsek E, et al. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure. Can J Cardiol. 2009;25:e353-e356.
23. Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation. 2005;111: 1504-1509.
24. Pataricza J, Krassoí I, Höhn J, et al. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther. 2003;17:115-121.
25. Grossini E, Caimmi PP, Molinari C, et al. Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig. J Cardiovasc Pharmacol. 2005;46:333-342.
26. Hajjar RJ, Schmidt U, Helm P, et al. Ca++ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther. 1997; 280:247-254.
27. Haikala H, Nissinen E, Etemadzadeh E, et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol. 1995;25:794-801.
28. Haikala H, Linden IB. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol. 1995;26(suppl 1):S10-S19.
29. Hasenfuss G, Pieske B, Castell M, et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98:2141-2147.
30. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002;23:1809-1840.
31. Tschöpe C, Kasner M, Westermann D, et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005;26: 2277-2284.
32. Hammerer-Lercher A, Puschendorf B, Mair J. Cardiac natriuretic peptides: new laboratory parameters in heart failure patients. Clin Lab. 2001; 47:265-277.